Psychedelics are receiving renewed attention within Western medicine as they represent potential treatments for many difficult-to-treat mental health disorders. However, psychedelic science is limited in its focus and inclusion of racial and ethnic minorities. Hence, this study examines whether race and ethnicity moderate the associations that naturalistic 3,4-methylenedioxymethamphetamine (MDMA)/ecstasy use and psilocybin use share with major depressive episodes (MDEs).
Method:
Data for this project are from The National Survey on Drug Use and Health (2005–2019). Participants were adults aged 18 years and older (unweighted N= 596,187). This study used multivariable logistic regression to test the interaction between race and ethnicity and MDMA/ecstasy use and psilocybin use for predicting lifetime, past year, and past year severe MDEs.
Results:
Race and ethnicity significantly moderated the associations between MDMA/ecstasy use and psilocybin use and MDEs. For White participants, MDMA/ecstasy use and psilocybin use each were associated with lowered odds of all three MDE outcomes (adjusted odds ratio (aOR) range: 0.82–0.92). For Hispanic participants, MDMA/ecstasy use and psilocybin use each conferred lowered odds of only a past year MDE (MDMA/ecstasy aOR: 0.82; psilocybin aOR: 0.79). For Non-Hispanic Racial Minority participants, MDMA/ecstasy and psilocybin use did not confer lowered odds of any MDE outcomes.
Conclusion:
Race and ethnicity have an impact on the associations that psychedelics share with mental health outcomes. Future research should explore the impact of identity and discrimination on the effects of psychedelics and should explore whether these substances can serve as effective treatments for minorities when used in culturally informed contexts.
AlbaughBJAndersonPO (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiat131: 1247–1250.
2.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: APA.
3.
ArgentoEBraschelMWalshZ, et al. (2018) The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J Psychopharmacol32: 1385–1391.
4.
ArgentoEStrathdeeSATupperK, et al. (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open7: e016025.
5.
BaileyZDKriegerNAgénorM, et al. (2017) Structural racism and health inequities in the USA: Evidence and interventions. The Lancet389: 1453–1463.
6.
BogenschutzMPForcehimesAAPommyJA, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
7.
Carhart-HarrisRBolstridgeMRuckerJ, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry3: 619–627.
8.
Carhart-HarrisRGiribaldiBWattsR, et al. (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med384: 1402–1411.
9.
Carhart-HarrisRRosemanLHaijenE, et al. (2018) Psychedelics and the essential importance of context. J Psychopharmacol32: 725–731.
10.
ColeJCBaileyMSumnallHR, et al. (2002) The content of ecstasy tablets: Implications for the study of their long-term effects. Addiction97: 1531–1536.
11.
DavisAKBarrettFSMayDG, et al. (2020) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78: 481–489.
12.
DavisAKXinYSepedaND, et al. (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress5: 24705470211035610.
13.
ErritzoeDSmithJFisherPM, et al. (2019) Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. J Psychopharmacol (Oxford, England)33: 1068–1075.
14.
FarréMAbanadesSRosetPN, et al. (2007) Pharmacological interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther323: 954–962.
15.
FeducciaAAJeromeLYazar-KlosinskiB, et al. (2019). Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Frontiers in Psychiatry10: 650.
16.
FriedmanSRTempalskiBBradyJE, et al. (2016) Income inequality, drug-related arrests, and the health of people who inject drugs: Reflections on seventeen years of research. Int J Drug Policy32: 11–16.
17.
FurukawaTAKesslerRCSladeT, et al. (2003) The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol Med33(2): 357–362.
18.
GaleaSVlahovD (2005) Urban health: Evidence, challenges, and directions. Annu Rev Public Health26: 341–365.
19.
GeorgeJRMichaelsTISeveliusJ, et al. (2019) The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. J Psychedelic Stud4: 4–15.
20.
GoldbergSBPaceBTNicholasCR, et al. (2020) The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research284: 112749.
21.
GriffithsRRJohnsonMWCarducciMA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxford, England)30: 1181–1197.
22.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
23.
HakeHSDavisJKPWoodRR, et al. (2019) 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav199: 343–350.
24.
HarariLLeeC (2021) Intersectionality in quantitative health disparities research: A systematic review of challenges and limitations in empirical studies. Soc Sci Med277: 113876.
25.
HartCLHartMZ (2019) Opioid crisis: Another mechanism used to perpetuate American racism. Cultur Divers Ethnic Minor Psychol25: 6–11.
26.
HawtonKCasañasIComabellaCHawC, et al. (2013) Risk factors for suicide in individuals with depression: A systematic review. J Affect Disord, 147(1–3): 17–28.
27.
HendricksPSCrawfordMSCropseyKL, et al. (2018) The relationships of classic psychedelic use with criminal behavior in the United States adult population. J Psychopharmacol32: 37–48.
HendricksPSThorneCBClarkCB, et al. (2015b) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol29: 280–288.
30.
HomanPBrownTHKingB (2021) Structural intersectionality as a new direction for health disparities research. J Health Soc Behav62: 350–370.
31.
JamesCVMoonesingheRWilson-FrederickSM, et al. (2017) Racial/ethnic health disparities among rural adults—United States, 2012-2015. Morbidity and Mortality Weekly Report. Surveillance Summaries66: 1–9.
32.
JohnsonMWGarcia-RomeuACosimanoMP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (Oxford, England)28: 983–992.
33.
JohnsonMWGriffithsRR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics14: 734–740.
34.
JohnsonMWHendricksPSBarrettFS, et al. (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther197: 83–102.
35.
JonesGMNockMK (2022a) Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol (Oxford, England)36: 57–65.
36.
JonesGMNockMK (2022b) MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol (Oxford, England)36: 46–56.
37.
JonesGMNockMK (2022c) Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. J Psychopharmacol (Oxford, England)36: 66–73.
38.
JonesGMNockMK (2022d) Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci Rep12: 2574.
39.
JonesGMNockMK (2022e) Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Sci Rep12: 16976.
40.
JonesGRicardJALipsonJ, et al. (2022) Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep12: 4099.
41.
KalantH (2001) The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ165: 917–928.
42.
LeonACOlfsonMPorteraL, et al. (1997) Assessing psychiatric impairment in primary care with the Sheehan disability scale. Int J Psychiat Med27: 93–105.
43.
LiechtiMEGammaAVollenweiderFX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacol154: 161–168.
McClureAF (1992) The Hippies and American values. Hist: Rev New Books21: 7.
46.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
OehenPTraberRWidmerV, et al. (2013) A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol27: 40–52.
49.
Ot’aloraGMGrigsbyJPoulterB, et al. (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol32: 1295–1307.
50.
ParadiesYBenJDensonN, et al. (2015) Racism as a determinant of health: A systematic review and meta-analysis. PloS One10: e0138511.
51.
PatelRTitheradgeD (2015) MDMA for the treatment of mood disorder: All talk no substance?Ther Adv Psychopharmacol5: 179–188.
52.
PisanoVDPutnamNPKramerHM, et al. (2017) The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol31: 606–613.
53.
PriestNDoeryKTruongM, et al. (2021) Updated systematic review and meta-analysis of studies examining the relationship between reported racism and health and well-being for children and youth: A protocol. BMJ Open11: e043722.
54.
RosenbergAGrovesAKBlankenshipKM (2017) Comparing Black and White drug offenders: Implications for racial disparities in criminal justice and reentry policy and programming. J Drug Issues47: 132–142.
SaleemiSPennybakerSJWooldridgeM, et al. (2017) Who is ‘molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol31: 1056–1060.
57.
SchenbergEE (2018) Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol9: 733–733.
58.
SessaB (2016) The history of psychedelics in medicine. In: von HeydenMJungaberleHMajićT (eds) Handbuch Psychoaktive Substanzen. Germany: Springer Berlin Heidelberg, pp.1–26.
59.
SmithDTFaberSCBuchananNT, et al. (2022) The need for psychedelic-assisted therapy in the Black community and the burdens of its provision. Front Psychiat12: 774736.
60.
ter BogtTFMEngelsRCMEDubasJS (2006) Party people: Personality and MDMA use of house party visitors. Addict Behav31: 1240–1244.
61.
UthaugMVDavisAKHaasTF, et al. (2021) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol (Oxford, England)36: 309–320.
62.
WilliamsMT (2020) Managing Microaggressions: Addressing Everyday Racism in Therapeutic Spaces. Oxford, UK: Oxford University Press.
63.
WilliamsMTDavisAKXinY, et al. (2020) People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Educ, Prev Policy28: 215–226.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
